Compounded Sema Injectable denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Compounded Semaglutide as Not FDA-Approved — and Why You Can Appeal

This denial reflects a fundamental regulatory distinction: compounded medications are prepared by a licensed pharmacy for an individual patient and are not required to go through the FDA's new-drug approval process. As a result, the compounded semaglutide injectable your prescriber ordered does not carry an FDA-approved label — even though the active ingredient (semaglutide) is present in FDA-approved branded products. UnitedHealthcare's coverage policy for many drugs requires that the specific product dispensed hold FDA approval, so the compounded form is automatically excluded.

This is a coverage policy decision, not a safety determination by the FDA. Compounded medications are lawfully prescribed and dispensed under federal and state pharmacy law. The denial is appealable, though it requires a clear clinical rationale for why the compounded form — rather than an FDA-approved alternative — is medically necessary for your specific situation.

## Your Federal Appeal Rights

Under ACA §2719 you have the right to independent external review after exhausting UHC's internal appeals. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review and access to the exact policy UHC applied. The external-review window is generally open for approximately four months after a final internal denial. If delay poses a serious health risk, request an expedited 72-hour review.

## The Concrete Appeal Process

1. Obtain UHC's written medical or coverage policy regarding compounded drugs and FDA-approval requirements. 2. File a Level 1 internal appeal with a prescriber letter explaining the clinical necessity of the compounded form specifically (not just semaglutide generally). 3. Escalate to external IRO review if the internal appeal is denied — external reviewers assess consistency with generally accepted medical practice, which may differ from UHC's internal FDA-approval standard.

## Documentation to Gather

• Diagnosis confirmation — chart notes, diagnostic codes, and clinical assessments for the underlying condition.
• Formulary and FDA-approved alternatives considered — documentation showing that the prescriber evaluated FDA-approved products in the same therapeutic class and the specific clinical reason(s) each is inappropriate for this patient (adverse effects experienced, inability to titrate, contraindication, or other individualized clinical factor).
• Clinical severity — chart documentation of the health burden requiring treatment and why timely, effective therapy matters.
• Prescriber medical-necessity letter — must explain specifically why the compounded preparation is medically necessary for this individual patient, not just why the drug class is appropriate. The letter should address each FDA-approved alternative individually.
• Compounding pharmacy documentation — documentation confirming the pharmacy is a licensed compounder operating under applicable federal and state law (e.g., 503A or 503B status), which addresses the lawfulness and quality-standard question.

## Criteria-Mapping Structure

| UHC Coverage Criterion | Response with Evidence | |---|---| | [Copy UHC's FDA-approval and compounding criteria verbatim] | [Prescriber rationale, pharmacy licensure documentation, and chart evidence that addresses each criterion] |

The strongest not-FDA-approved appeals combine (1) clear documentation that FDA-approved alternatives were evaluated and are clinically unsuitable for this patient, and (2) confirmation that the compounding pharmacy meets applicable regulatory standards — addressing both the "why not the approved product" and "why the compounded product is appropriate" questions simultaneously.